Stahl SM. Selective histamine H1 antagonism: novel hypnoticand pharmacologic actions challenge classical notions of antihistamines[J]. CNS Spectrums, 2008, 13(12):1027-1038.
[5]
Owen RT. Selective histamine H1 antagonism: a novel approach to insomnia using low dose doxepin[J]. Drugs Today, 2009,45:261-267.
[6]
Roth T, Rogowski R, Hull S,et al. Efficacy and safety of doxepin 1mg,3mg,and 6mg in adults with primary insomnia[J]. Sleep, 2007,30(11):1555-1561.
[7]
Roth T,Durrence H, Gotfried M, et al. Efficacy and safety of doxepin 1 and 3mg in a 3-month trial of elderly adults with chronic insomnia[J]. Sleep,2008,31:A230.
[8]
Krystal AD,Durrence HH,Scharf M,et al. Efficacy and safety of doxepin 1 and 3mg in a 12-week sleep laboratory and outpatient trial of elderly subjeects with chronic primary insomnia [J].Sleep,2010,33(11):1553-1561.
[9]
Jigar K, Anaada KK, Jaykumar JS, et al. Therapetic rationale for low dose doxepin in insomnia patients[J]. Asian Pacific Journal of Tropical Disease, 2013,3(6):331-336.
[10]
World Health Organization. International Statistical Classification of Diseas and related health problems. 10th version[M].Geneva: World Health Organizzation,1994.
[11]
Buysse DJ, Reynolds CF, Monk TH, et al. The pittsburgh sleep quality index: A new instrument for psychiatric practice and research[J]. Psychiatric Research,1989,28(2):193.
